Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Screening for Germline EGFR

Screening for Germline EGFR BRIEF REPoRT Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping Geoffrey R. Oxnard, MD,* Vincent A. Miller, MD,* Mark E. Robson, MD,† Christopher G. Azzoli, MD,* William Pao, MD, PhD,‡ Marc Ladanyi, MD,§ and Maria E. Arcila, MD§ Conclusions: Genotyping of lung cancers, now commonly per- Introduction: The study of patients carrying germline endothelial formed to predict benefit from treatment with EGFR tyrosine kinase growth factor receptor (EGFR) mutations, which have been found in inhibitors, can also be used as a screening tool to identify patients cases of familial lung adenocarcinoma, could provide unique insight into at risk of carrying germline EGFR mutations. o nce identified, these lung cancer risk and carcinogenesis in never-smokers. However, inves- patients and their families can be studied prospectively to explore tigations into the biology of germline EGFR mutations have been ham- appropriate lung cancer screening strategies. Further studies using pered by the lack of an effective strategy for screening for carriers. We existing oncogenomic data to provide insight into underlying ger- hypothesized that patients with lung cancers found to harbor the EGFR mline genetics are warranted. T790M resistance mutation before treatment, an uncommon occurrence, would be likely to carry underlying germline http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Screening for Germline EGFR

Journal of Thoracic Oncology , Volume 7 (6) – Jun 1, 2012

Loading next page...
 
/lp/wolters-kluwer-health/screening-for-germline-egfr-NRW57HyylC

References (19)

Copyright
Copyright © 2012 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e318250ed9d
pmid
22588155
Publisher site
See Article on Publisher Site

Abstract

BRIEF REPoRT Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping Geoffrey R. Oxnard, MD,* Vincent A. Miller, MD,* Mark E. Robson, MD,† Christopher G. Azzoli, MD,* William Pao, MD, PhD,‡ Marc Ladanyi, MD,§ and Maria E. Arcila, MD§ Conclusions: Genotyping of lung cancers, now commonly per- Introduction: The study of patients carrying germline endothelial formed to predict benefit from treatment with EGFR tyrosine kinase growth factor receptor (EGFR) mutations, which have been found in inhibitors, can also be used as a screening tool to identify patients cases of familial lung adenocarcinoma, could provide unique insight into at risk of carrying germline EGFR mutations. o nce identified, these lung cancer risk and carcinogenesis in never-smokers. However, inves- patients and their families can be studied prospectively to explore tigations into the biology of germline EGFR mutations have been ham- appropriate lung cancer screening strategies. Further studies using pered by the lack of an effective strategy for screening for carriers. We existing oncogenomic data to provide insight into underlying ger- hypothesized that patients with lung cancers found to harbor the EGFR mline genetics are warranted. T790M resistance mutation before treatment, an uncommon occurrence, would be likely to carry underlying germline

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Jun 1, 2012

There are no references for this article.